A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).

被引：0
|
作者：
Janne, PA
Obasaju, C
Simon, G
Taub, R
Kelly, K
Fidias, P
Bloss, LP
Kindler, HL
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Lilly Oncol, Indianapolis, IN USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Univ Nacl Colombia, New York, NY USA
[5] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[6] Univ Chicago, Ctr Med, Chicago, IL USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7053
引用
收藏
页码：629S / 629S
页数：1
相关论文
共 50 条
  • [31] Radiological Response Patterns in Malignant Pleural Mesothelioma (MPM): Subgroup Analyses of the Phase 2 Stellar Trial of TTFields Plus Chemotherapy for First-Line Treatment
    Grosso, F.
    Ceresoli, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S147 - S148
  • [32] 2nd line chemotherapy for patients with malignant mesothelioma (MPM) pretreated with pemetrexed (PMTX) and platinum (P).
    Karthaus, M
    Frieler, F
    Plahl, A
    Wert, N
    Tagizadeh, K
    Metzner, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
  • [33] Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/gemcitabine
    Serke, Monika
    Xanthopoulos, Anastasios
    Bauer, Thorsten
    ANNALS OF ONCOLOGY, 2006, 17 : 231 - 231
  • [34] Tumor treating fields plus chemotherapy for first-line malignant pleural mesothelioma (MPM): Radiological responses in the STELLAR trial
    Grosso, F.
    Ceresoli, G. L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Irinotecan in combination with gemcitabine as second-line chemotherapy in patients with malignant pleural mesothelioma previously treated with pemetrexed-cisplatin regimen: a phase 2 study
    Fukuoka, Kazuya
    Nakano, Takashi
    Kuribayashi, Kozo
    Iida, Shin-ichiro
    Tamura, Kunihiro
    Tabata, Chiharu
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S771 - S771
  • [36] Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
    Zucali, Paolo A.
    Ceresoli, Giovanni L.
    Garassino, Isabella
    De Vincenzo, Fabio
    Cavina, Raffaele
    Campagnoli, Elisabetta
    Cappuzzo, Federico
    Salamina, Silvia
    Parra, Hector J. Soto
    Santoro, Armando
    CANCER, 2008, 112 (07) : 1555 - 1561
  • [37] Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM)
    Krug, Lee M.
    Wozniak, Antoinette J.
    Kindler, Hedy Lee
    Feld, Ronald
    Koczywas, Marianna
    Morero, Jose Luis
    Rodriguez, Cristina P.
    Ross, Helen J.
    Bauman, Julie E.
    Orlov, Sergey V.
    Ruckdeschel, John C.
    Mita, Alain C.
    Fein, Luis
    Fernandez, Cristian
    Hall, Robert
    Kawabe, Takumi
    Sharma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Chemotherapy with gemcitabine and oxaliplatin in 13 malignant pleural mesothelioma (MPM):: A monocenter experience.
    Brechot, JM
    Morère, JF
    Des Guetz, G
    Chouhania, K
    Breau, JL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 678S - 678S
  • [39] Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma
    Scagliotti, GV
    Shin, DM
    Kindler, HL
    Vasconcelles, MJ
    Keppler, U
    Manegold, C
    Burris, H
    Gatzemeier, U
    Blatter, J
    Symanowski, JT
    Rusthoven, JJ
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1556 - 1561
  • [40] Phase I clinical trial of antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of advanced pleural mesothelioma
    Hassan, R.
    Sharon, E.
    Chen, H. X.
    Conlon, K.
    Ling, A.
    Steinberg, S. M.
    Pastan, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345